Tradestie Institutional Equity Comparison Engine
TCMD vs BMRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TCMD Overall Edge
TCMD Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Tactile Systems Technology, Inc. (TCMD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, TCMD trades at 18.2x Forward P/E with 9.4% operating margin (+7.1% YoY revenue) versus BMRA at N/M Forward P/E and -125.2% operating margin (-8.3% YoY). In options structure, TCMD sits in CONSOLIDATION (15th %ile IV; Dealer Gamma Walls on Pro) against BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
TCMD
TCMD 18.2x vs BMRA N/M Fwd P/E
Growth & Margin Winner
TCMD
Op Margin 9.4% vs -125.2% ยท YoY +7.1% vs -8.3%
Momentum & Technical Winner
TCMD
1Y +8.2% vs -46.9% ยท 52W Pos 34% vs 4%
Options & Structure Winner
TCMD
CONSOLIDATION (15th %ile IV) vs UNCLASSIFIED (N/A IV)
TCMD
NASDAQ
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$26.36
-1.68% 1D
Market Cap
$601.1M
1M Return
+17.05%
1Y Return
+8.17%
Forward P/E
18.2x
Unified AI Score
25.0 / 100
SELL
Tech 50.0
Fund 27.0
Flow 66.0
Mom 21.4
BMRA
NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap
$6.0M
1M Return
-28.19%
1Y Return
-46.86%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
TCMD +8.17%
BMRA -46.86%
Spread: +55.03 pp (TCMD Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | TCMD Revenue | BMRA Revenue | TCMD Op. Margin | BMRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $190M | $10M | 5.5% | -46.4% | TCMD |
| FY2020 | $190M | $10M | -1.9% | -41.0% | TCMD |
| FY2021 | $210M | $10M | -0.8% | -104.2% | TCMD |
| FY2022 | $250M | $20M | -5.2% | -24.0% | TCMD |
| FY2023 | $270M | $10M | 6.6% | -135.3% | TCMD |
| FY2024 | $290M | $10M | 7.6% | -117.6% | TCMD |
| FY2025 | $330M | $10M | 8.9% | -96.7% | TCMD |
| FY2026 | N/A | $0M | N/A | -119.5% | BMRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TCMD | BMRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $601.1M | $6.0M | Larger Scale | TCMD |
| Trailing P/E Ratio Valuation | 26.1x | N/M | Lower Multiple | TCMD |
| Forward P/E Ratio Valuation | 18.2x | N/M | Lower Multiple | TCMD |
| Revenue Growth (YoY) Growth | +7.1% | -8.3% | Higher Growth | TCMD |
| Operating Margin (TTM) Profitability | 9.4% | -125.2% | Higher Margin | TCMD |
| Net Profit Margin Profitability | 6.7% | -115.5% | Higher Margin | TCMD |
| Return on Equity (ROE) Capital Efficiency | 11.0% | -113.8% | Higher ROE | TCMD |
| 52-Week Range Position Momentum | 34% ($21โ$38) | 4% ($1โ$3) | Stronger Trend | TCMD |
| Beta / 30D Volatility Risk Regime | 1.00ฮฒ ยท 53% Vol | 0.67ฮฒ ยท 62% Vol | Lower Realized Risk | TCMD |
| Unified Institutional Score Composite Signal | 25.0 / 100 (SELL) | 44.5 / 100 (HOLD) | Higher Composite | BMRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full TCMD vs BMRA Buy Guide
TCMD
CONSOLIDATION
94d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
15th %ile
IV Regime
Compressed (<25th %ile)
BMRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither TCMD nor BMRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.